The global Addison disease testing market is set to experience steady growth, driven by the growing emphasis on early detection and rising healthcare expenditures. The market is projected to reach a valuation of US$ 249.8 million in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 3.4% over the forecast period. By 2033, the market is anticipated to be valued at approximately US$ 349.7 million, according to a report by Future Market Insights.
Addison’s disease, a rare but potentially life-threatening disorder, presents with non-specific symptoms such as fatigue, weight loss, and low blood pressure, making early diagnosis critical. Due to its variable presentation, healthcare providers emphasize a high degree of clinical suspicion and early testing for better disease management. This push for early diagnosis is a key driver for the Addison disease testing market.
The introduction of emergency medical alert cards for Addison’s disease patients is also playing a pivotal role in driving demand for testing. These cards, which inform healthcare professionals of a patient’s condition during emergencies, highlight the need for proper testing and early intervention. As healthcare systems prioritize preventive care and early diagnosis, the demand for Addison disease testing is expected to increase globally.
A Detailed Full Report – https://www.futuremarketinsights.com/reports/addison-disease-testing-market
Key Takeaways:
- The global Addison disease testing market is projected to grow at a CAGR of 3.4%, reaching a valuation of US$ 349.7 million by 2033, up from US$ 249.8 million in 2023.
- The mutable nature of Addison’s disease symptoms necessitates early and accurate testing to facilitate timely medical intervention.
- The introduction of emergency medical alert cards for Addison’s disease patients is increasing awareness and demand for early testing.
- Rising healthcare spending and a shift toward early diagnosis and preventive healthcare are further driving growth in the global Addison disease testing market.
With increased emphasis on early diagnosis and the availability of emergency medical alert systems, the Addison disease testing market is set to grow steadily. As healthcare providers push for better disease management and improved patient outcomes, testing solutions for Addison’s disease will continue to see increased adoption.
Key Market Drivers
- Increased Healthcare Spending: Growing investments in healthcare infrastructure and services are enhancing diagnostic capabilities, leading to increased demand for Addison disease testing.
- Introduction of Emergency Cards: The implementation of emergency identification cards for patients with Addison’s disease is raising awareness and promoting early testing and diagnosis, which is crucial for effective management of the condition.
- Rising Awareness of Addison’s Disease: There is a growing recognition of the symptoms and risks associated with Addison’s disease among both healthcare professionals and the general public, leading to earlier diagnosis and increased testing rates.
- High Index of Suspicion for Diagnosis: Given the nonspecific symptoms associated with Addison’s disease, a heightened awareness and suspicion among clinicians can lead to more frequent testing, thus driving market growth.
- Increase in Autoimmune Disorders: The rising prevalence of autoimmune disorders, which are often associated with Addison’s disease, is contributing to a greater demand for diagnostic testing.
Regional Insights
- North America: This region holds the largest market share (approximately 35.2%) due to high healthcare spending, advanced diagnostic technologies, and significant awareness campaigns regarding Addison’s disease.
- Europe: With a market share of about 27.7%, Europe is also witnessing growth driven by increasing awareness and improvements in healthcare infrastructure.
- Asia-Pacific: This region is expected to see rapid growth as awareness increases and healthcare systems improve, leading to higher testing rates for Addison’s disease.
Who are the Key Players in the Global Addison Disease Testing Market?
Some of the players in the Addison Disease Testing service market involve Diagnostic Laboratory Services, Inc., Any Lab Test Now, Dr. Lal PathLabs, Laboratory Corporation of America Holdings, Sonora Quest Laboratories, Core Diagnostics Private Limited, Ayumetrix, and others.
- In May 2021, AdrenalinMD launched a home testing kit for Addison’s disease. This kit allows people to test their own blood levels of cortisol and ACTH, and it can be used to diagnose Addison’s disease or to monitor treatment.
- In January 2020, the FDA approved a new blood test called the Synacthen Depot Test for the diagnosis of Addison’s disease. This test is more accurate than the traditional ACTH stimulation test, and it can be performed in a doctor’s office.
- In February 2020, Dr. Lal PathLabs Ltd, a Gurugram-based public diagnostics chain, spent around Rs 7.7 crore (a little over $1 million at the current exchange rate) to acquire two pathological laboratories in Maharashtra.
- In February 2021, Genalyte, a healthcare diagnostics and analytics company, and Sonora Quest Laboratories, the market share leader in diagnostic laboratory testing in Arizona, announced a strategic partnership with Cigna Medicare Arizona to leverage science-based analytics to reduce costs while improving clinical outcomes for customers of Cigna Arizona’s Medicare Advantage plans.
Key Market Players
- Diagnostic Laboratory Services Inc.
- Any Lab Test Now
- Dr. Lal PathLabs
- Laboratory Corporation of America Holdings
- Sonora Quest Laboratories
- Core Diagnostics Private Limited
- Ayumetrix
Key Segments Covered in the Addison Disease Testing Industry Survey
By Testing Type:
- Laboratory
- Comprehensive Metabolic Panel
- Thyroid-Stimulating Hormone (TSH) Levels
- ACTH Stimulation
- Insulin-induced Hypoglycaemia
- Autoantibody
- Prolactin
- Imaging Studies
- Chest Radiograph
- Computed tomography (CT) Scan
By End User:
- Hospitals
- Clinics
- Diagnostics Laboratories
By Region:
- North America
- Europe
- Asia-Pacific
- Middle East & Africa
- Latin America
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
Sonohysterography Catheters Market
Osteotomy Plates Market
Thoracic Vascular Stent Grafts Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube